BYSI News and Press, BeyondSpring Inc. From 08/17/20

Our analysis concludes BeyondSpring Inc. ( BYSI ) offers investors exponential gain potential if BYSI's first NDA submitted in China and anticipated NDA submission in the United States are approved. This is because BYSI's product, Plinabulin, has estimated peak revenue potential in the billion...

- NCCN Guideline Updates Highlight Need for Maximum CIN Prevention and Resource Allocation for COVID-19 Patients - - First Patient Dosed in the U.S. Avoided Grade 4 Neutropenia in Cycle 2 with Plinabulin and Pegfilgrastim, Despite Experiencing Grade 4 Neutropenia in Cycle 1 with Pegfi...

NEW YORK, June 30, 2020 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative immuno-oncology cancer therapies, today announced that the Company presen...

Research Presented at 2020 AACR Virtual Annual Meeting The Triple I/O Combination of Plinabulin, Anti-PD-1 and Radiation Achieved a 100 Percent Complete Response in Anti-PD-1 Non-responsive Animal Model Triple I/O Combination to Be Administered to Patients Who Failed I/O in Second...

Shares of BeyondSpring (NASDAQ: BYSI) -- a clinical-stage biopharmaceutical company -- are down by 18.1% as of 11:26 a.m. EDT on Friday, following the drugmaker's announcement of the pricing of a public offering of ordinary shares. With the company set to dilute existing shareholders, it isn...

Gainers:  Broadway Financial (NASDAQ: BYFC ) +195% . More news on: Broadway Financial Corporation, Cohen & Company Inc., LM Funding America, Inc., Stocks on the move, , Read more ...

BeyondSpring (NASDAQ: BYSI )  -20%  after pricing ordinary shares. More news on: BeyondSpring Inc., Obalon Therapeutics, Inc., Repro Med Systems, Inc., Stocks on the move, , Read more ...

BeyondSpring (NASDAQ: BYSI ) has priced its public offering of 1.93M ordinary shares at $13.00/share. More news on: BeyondSpring Inc., Healthcare stocks news, , Stocks on the move, Read more ...

Clinical-stage biopharma BeyondSpring (NASDAQ: BYSI ) rose 7.2% in the immediate wake of positive results from a late-stage study of its lead drug candidate plinabulin (combined with Amgen's Neulasta). More news on: BeyondSpring Inc., Notable Calls, Healthcare stocks news, Read mor...

Edesa Biotech (NASDAQ: EDSA ) +218%  on launch of COVID-19 study in Canada. More news on: Edesa Biotech, Inc., Brickell Biotech, Inc., BioHiTech Global, Inc., Stocks on the move, , Read more ...